Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Shareholders' Deficit

v3.22.2.2
Condensed Consolidated Statement of Changes in Shareholders' Deficit - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Payable [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Mar. 31, 2021 $ 500 $ 56,075 $ 56,649,491 $ 136,000 $ (53,683,268) $ (87,830) $ 3,070,969
Beginning balance, shares at Mar. 31, 2021 5,000,000 607 560,745,180            
Beneficial conversion feature related to the Series E Preferred Shares 3,269,505 3,269,505
Amortization of beneficial conversion feature related to Series E Preferred Shares (817,376) (817,376)
Common stock vested to consultants $ 13 48,738 24,900 73,651
Net loss             (2,562,743)   (2,562,743)
Common stock vested to consultants, shares     125,000            
Issuance of common stock upon conversion $ 133 421,353 421,486
Issuance of common stock upon conversion, shares     1,329,246            
Conversion of Series B PS to common stock $ 314 (314)
Conversion of Series B PS to common stock, shares   (262) 3,144,000            
Conversion of Series D PS to common stock $ 43 (43)
Conversion of Series D PS to common stock, shares     428,572            
Exchange of Series D PS to Series E PS (3,258,189) (3,258,189)
Sale of common shares and warrants for cash, less offering costs and commitment shares $ 3,577 17,273,546 17,277,123
Sale of common shares and warrants for cash, less offering costs and commitment shares, shares     35,772,729            
Exercise of warrants related to the sale of common shares $ 110 10,890 11,000
Exercise of warrants related to the sale of common shares, shares     1,100,000            
Redemption of Series D Preferred shares (2,534,758) (2,534,758)
Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity (3,087,830) 2,000,000 87,830 (1,000,000)
Common shares to be issued for Patent acquisition 5,000,000 5,000,000
Ending balance, value at Jun. 30, 2021 $ 500 $ 60,265 74,585,336 7,160,900 (62,856,334) 18,950,668
Ending balance, shares at Jun. 30, 2021 5,000,000 345 602,644,727            
Beginning balance, value at Mar. 31, 2021 $ 500 $ 56,075 56,649,491 136,000 (53,683,268) (87,830) 3,070,969
Beginning balance, shares at Mar. 31, 2021 5,000,000 607 560,745,180            
Net loss                 (5,412,378)
Ending balance, value at Sep. 30, 2021 $ 500 $ 60,683 74,609,294 11,948,176   (67,408,142) 19,210,511
Ending balance, shares at Sep. 30, 2021 5,000,000 345 606,821,513            
Beginning balance, value at Jun. 30, 2021 $ 500 $ 60,265 74,585,336 7,160,900 (62,856,334) 18,950,668
Beginning balance, shares at Jun. 30, 2021 5,000,000 345 602,644,727            
Conversion of Series E PS to common stock     $ 411 (411)    
Conversion of Series E PS to common stock, shares     4,114,286            
Amortization of beneficial conversion feature related to Series E Preferred Shares     (1,341,948) (1,341,948)
Dividends payable on Preferred Shares     (177,586) (177,586)
Common stock vested to consultants   $ 6 24,369 24,900     49,275
Net loss       (2,849,635) (2,849,635)
Common stock vested to consultants, shares     62,500            
Revision of dividends payable on Series B Preferred Shares (See Note 2)         (182,639)   (182,639)
Common shares to be issued for Technical and Equipment Rights Agreement       4,762,376   4,762,376
Ending balance, value at Sep. 30, 2021 $ 500 $ 60,683 74,609,294 11,948,176   (67,408,142) 19,210,511
Ending balance, shares at Sep. 30, 2021 5,000,000 345 606,821,513            
Beginning balance, value at Mar. 31, 2022 $ 500 $ 67,500 96,701,607 20,132,650   (150,036,023) (33,133,766)
Beginning balance, shares at Mar. 31, 2022 5,000,000 674,644,124            
Common stock issued for legal settlement to NSH shareholders $ 6,112 19,311,486 (19,317,598)
Common stock issued for legal settlement to NSH shareholders, shares     61,154,136            
Conversion of Series E PS to common stock $ 454 839,546 840,000
Conversion of Series E PS to common stock, shares     4,537,240            
Beneficial conversion feature related to the Series E Preferred Shares 99,000 (99,000)
Amortization of beneficial conversion feature related to Series E Preferred Shares (42,500) (42,500)
Accretion of Series E Preferred Shares (278,500) (278,500)
Dividends payable on Preferred Shares (102,227) (102,227)
Common stock issued in business agreement $ 25 56,225 (56,250)
Common stock issued in business agreement ,shares     250,000            
Common stock vested to consultants $ 6 24,369 24,375
Net loss             (2,200,176) (2,200,176)
Ending balance, value at Jun. 30, 2022 $ 500 $ 74,097 117,032,233 815,052 (56,250) (152,758,426) (34,892,794)
Ending balance, shares at Jun. 30, 2022 5,000,000 740,585,500            
Beginning balance, value at Mar. 31, 2022 $ 500 $ 67,500 96,701,607 20,132,650   (150,036,023) (33,133,766)
Beginning balance, shares at Mar. 31, 2022 5,000,000 674,644,124            
Net loss                 (26,728,521)
Increase of 10% in Series E Preferred Shares to one holder based on certain rights                 156,000
Ending balance, value at Sep. 30, 2022 $ 75,170 118,061,820 662,767 (56,250) (177,927,198) (59,183,191)
Ending balance, shares at Sep. 30, 2022 751,322,954            
Beginning balance, value at Jun. 30, 2022 $ 500 $ 74,097 117,032,233 815,052 (56,250) (152,758,426) (34,892,794)
Beginning balance, shares at Jun. 30, 2022 5,000,000 740,585,500            
Common stock issued for legal settlement to NSH shareholders $ 40 127,646 (127,686)
Common stock issued for legal settlement to NSH shareholders, shares     404,067            
Amortization of beneficial conversion feature related to Series E Preferred Shares (42,500) (42,500)
Accretion of Series E Preferred Shares (278,500) (278,500)
Dividends payable on Preferred Shares (55,427) (55,427)
Common stock issued in business agreement $ 25 25,975   26,000
Common stock issued in business agreement ,shares     250,000            
Common stock vested to consultants $ 6 24,369 24,375
Net loss             (24,528,345) (24,528,345)
Conversion of Series E Preferred Shares to common stock $ 992 827,008 (108,000) 720,000
Conversion of Series E Preferred Shares to common stock, shares     9,920,887            
Increase of 10% in Series E Preferred Shares to one holder based on certain rights (156,000) (156,000)
Common stock issued from shares payable $ 10 24,590 (24,600)  
Common stock issued from shares payable, shares     100,000            
Common stock vested to consultants, shares     62,500            
Ending balance, value at Sep. 30, 2022 $ 75,170 $ 118,061,820 $ 662,767 $ (56,250) $ (177,927,198) $ (59,183,191)
Ending balance, shares at Sep. 30, 2022 751,322,954